Background
Methods
Patients’ data
SBRT treatment
Stereotactic body radiation therapy | |
---|---|
Irradiation dose delivered
| |
12 Gy × 4 fractions three times per week | 11 (47.8%) |
10 Gy × 5 fractions three times per week | 9 (39.1%) |
8 Gy × 7 fractions three times per week | 3 (13.0%) |
Active breathing control
| 23 (100%) |
Cone-beam CT guiding
| 23 (100%) |
PTV volume (cm
3
)
| |
Median | 48.4 |
Range | 26.0-110.2 |
Lung volume (cm
3
)
| |
Total lung (median) | 2301.4 |
(range) | 1983.4-2950.5 |
Contralateral lung (median) | 1373.4 |
(range) | 1255.8-1712.3 |
Ipsilateral lung (median) | 942.2 |
(range) | 786.8-1233.4 |
Systematic treatment
| |
Chemotherapy
| |
Concurrent chemotherapy | 1 (4.3%) |
Sequential chemotherapy | 14 (60.9%) |
Tyrosine kinase inhibitor
a
| 3 (13.0%) |
None
| 5 (21.7%) |
Treatment assessment and follow-up
Statistical methods
Results
Characteristics | Number of patients (%) |
---|---|
Age (years)
| |
Median (range) | 58 (45–74) |
Gender
| |
Male/Female | 17 (73.9)/6 (26.1) |
ECOG
a
performance status
| |
0-1 | 21 (91.3) |
2 | 2 (8.7) |
Pathology of the primary tumor
| |
Squamous-cell lung cancer | 10 (43.5) |
Non-squamous cell lung cancer | 10 (43.5) |
Sarcomatoid carcinoma | 2 (8.7) |
Small cell lung cancer | 1 (4.3) |
Surgical method
| |
Right upper lung lobectomy | 9 (39.1) |
Right lower lung lobectomy | 3 (13.0) |
Left upper lung lobectomy | 5 (21.7) |
Left lower lung lobectomy | 4 (17.4) |
Left pneumonectomy | 2 (8.7) |
T staging after surgery
b
| |
T1/T2/T3/T4 | 3 (13.0)/11 (47.8)/8 (34.8)/1(4.3) |
N staging after surgery
b
| |
N0/N1/N2 | 10 (43.5)/6 (26.1)/7 (30.4) |
Tumor stage after surgery
b
| |
I | 6 (26.1) |
II | 9 (39.1) |
III | 8 (34.8) |
Time from surgery to lung metastasis (months)
| |
Median (range) | 16.0 (4.0-75.0) |
Sites of lung metastasis
| |
Contralateral lung of the primary tumor | 12 (52.2) |
Ipsilateral lung of the primary tumor | 11 (47.8) |
Follow-up time since diagnosis of lung metastasis (months)
| |
Median (range) | 14.0 (6.0-47.0) |
Treatment
Local control and survival
Treatment-related toxicities
Toxicities
b
| Toxicity grades, n (%) | ||||
---|---|---|---|---|---|
Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
Radiation pneumonitis
| |||||
Cough | 9 (39.1) | 7 (30.4) | 4 (17.4) | 2 (8.7) | 1 (4.3)
c
|
Shortness of breath | 21 (91.3) | 0 | 1 (4.3) | 0 | 1 (4.3)
c
|
Other treatment-related toxicities
| |||||
Chest wall pain | 22 (95.7) | 0 | 1 (4.3) | 0 | 0 |
Acute esophagitis | 21 (91.3) | 0 | 2 (8.7) | 0 | 0 |
Correlations between lung parameters and incidence of RP
Grade ≥2 RIP (n = 8) | Grade 0–1 RIP (n = 15) |
p value | |
---|---|---|---|
mean ± SD | mean ± SD | ||
Total Lungs
| |||
V5 (%)
c
| 36.0 ± 6.0 | 35.0 ± 4.0 | 0.141 |
V10 (%)
c
| 16.0 ± 4.0 | 14.0 ± 2.0 | 0.125 |
V20 (%)
c
| 4.8 ± 2.0 | 4.4 ± 1.2 | 0.696 |
V30 (%)
c
| 2.0 ± 1.0 | 2.0 ± 1.0 | 0.990 |
MLD (Gy)
d
| 3.8 ± 1.6 | 3.7 ± 1.3 | 0.077 |
Contralateral lungs
| |||
V5 (%) | 26.0 ± 7.0 | 25.0 ± 9.0 | 0.421 |
V10 (%) | 18.0 ± 7.0 | 16.0 ± 9.0 | 0.277 |
V20 (%) | 3.2 ± 1.1 | 2.4 ± 0.9 | 0.210 |
V30 (%) | 1.6 ± 0.5 | 1.6 ± 0.6 | 0.992 |
MLD (Gy) | 2.8 ± 0.6 | 2.6 ± 0.2 | 0.483 |
Ipsilateral lungs
| |||
V5 (%) | 51.0 ± 9.1 | 44.0 ± 4.0 | 0.034 |
V10 (%) | 22.0 ± 6.0 | 19.0 ± 4.0 | 0.273 |
V20 (%) | 6.0 ± 2.8 | 5.2 ± 2.2 | 0.454 |
V30 (%) | 2.6 ± 1.0 | 2.8 ± 1.1 | 0.824 |
MLD (Gy) | 5.9 ± 1.3 | 5.7 ± 1.1 | 0.290 |
PTV volume (cm
3
)
| 59.0 ± 9.6 | 45.0 ± 9.9 | 0.039 |
Parameters | Optimal threshold | ||
---|---|---|---|
Value | Sensitivity | Specificity | |
PTV volume (cm3) | 59 | 75.0% | 80.0% |
Ipsilateral lung V5
d
(%) | 51 | 62.5% | 80.0% |